Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection

被引:31
作者
Buijs, P. R. A. [1 ]
van Eijck, C. H. J. [1 ]
Hofland, L. J. [2 ]
Fouchier, R. A. M. [3 ]
van den Hoogen, B. G. [3 ]
机构
[1] Erasmus MC, Dept Surg, NL-3015 CE Rotterdam, Netherlands
[2] Erasmus MC, Dept Internal Med, Div Endocrinol, NL-3015 CE Rotterdam, Netherlands
[3] Erasmus MC, Dept Virosci, NL-3015 CE Rotterdam, Netherlands
关键词
pancreatic adenocarcinoma; oncolytic virotherapy; Newcastle disease virus; innate immunity; I INTERFERONS; CANCER-CELLS; TUMOR-CELLS; THERAPY; NDV; REPLICATION; TRIAL; CHEMOTHERAPY; GEMCITABINE; VIROTHERAPY;
D O I
10.1038/cgt.2013.78
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Newcastle disease virus (NDV) is a naturally occurring oncolytic virus with clinically proven efficacy against several human tumor types. Selective replication in and killing of tumor cells by NDV is thought to occur because of differences in innate immune responses between normal and tumor cells. In our effort to develop oncolytic virotherapy with NDV for patients with pancreatic cancer, we evaluated the responses to NDV infection and interferon (IFN) treatment of 11 different established human pancreatic adenocarcinoma cell lines (HPACs). Here we show that all HPACs were susceptible to NDV. However, this NDV infection resulted in different replication kinetics and cytotoxic effects. Better replication resulted in more cytotoxicity. No correlation was observed between defects in the IFN pathways and, NDV replication or NDV-induced cytotoxicity. IFN production by HPACS after NDV infection differed substantially. Pretreatment of HPACs with IFN resulted in diminished NDV replication and decreased the cytotoxic effects in most HPACs. These findings Suggest that not all HPACs have functional defects in the innate immune pathways, possibly resulting in resistance to oncolytic virus treatment. These data support the rationale for designing recombinant oncolytic NDVs with optimized virulence that should likely contain an antagonist of the IFN pathways.
引用
收藏
页码:24 / 30
页数:7
相关论文
共 45 条
[11]   An optimized clinical regimen for the oncolytic virus PV701 [J].
Hotte, Sebastien J. ;
Lorence, Robert M. ;
Hirte, Hal W. ;
Polawski, Susan R. ;
Bamat, Michael K. ;
O'Neil, James D. ;
Roberts, M. Scot ;
Groene, William S. ;
Major, Pierre P. .
CLINICAL CANCER RESEARCH, 2007, 13 (03) :977-985
[12]   Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy [J].
Janke, M. ;
Peeters, B. ;
de Leeuw, O. ;
Moorman, R. ;
Arnold, A. ;
Fournier, P. ;
Schirrmacher, V. .
GENE THERAPY, 2007, 14 (23) :1639-1649
[13]   Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2 [J].
Janke, Markus ;
Peeters, Ben ;
Zhao, Heng ;
De Leeuw, Olav ;
Moorman, Rob ;
Arnold, Annette ;
Ziouta, Yvonne ;
Fournier, Philippe ;
Schirrmacher, Volker .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 33 (04) :823-832
[14]   Response of pancreatic cancer cells treated with interferon-α or β and co-exposed to ionising radiation [J].
Joest, Eva ;
Roos, Wynand P. ;
Kaina, Bernd ;
Schmidberger, Heinz .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2010, 86 (09) :732-741
[15]   Transfecting mammalian cells: Optimization of critical parameters affecting calcium-phosphate precipitate formation [J].
Jordan, M ;
Schallhorn, A ;
Wurm, FM .
NUCLEIC ACIDS RESEARCH, 1996, 24 (04) :596-601
[16]   Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines [J].
Krishnamurthy, Sateesh ;
Takimoto, Toru ;
Scroggs, Ruth Ann ;
Portner, Allen .
JOURNAL OF VIROLOGY, 2006, 80 (11) :5145-5155
[17]   Experimental human metapneumovirus infection of cynomolgus Macaques (Macaca fascicularis) results in virus replication in ciliated epithelial cells and pneumocytes with associated lesions throughout the respiratory tract [J].
Kuiken, T ;
van den Hoogen, BG ;
van Riel, DAJ ;
Laman, JD ;
van Amerongen, G ;
Sprong, L ;
Fouchier, RAM ;
Osterhaus, ADME .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (06) :1893-1900
[18]   Velogenic Newcastle Disease Virus as an Oncolytic Virotherapeutics: In Vitro Characterization [J].
Kumar, Rajiv ;
Tiwari, Ashok K. ;
Chaturvedi, Uttara ;
Kumar, G. Ravi ;
Sahoo, Aditya P. ;
Rajmani, R. S. ;
Saxena, Lovleen ;
Saxena, Shikha ;
Tiwari, Sangeeta ;
Kumar, Sudesh .
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2012, 167 (07) :2005-2022
[19]   The Oncolytic Activity of Newcastle Disease Virus NDV-HUJ on Chemoresistant Primary Melanoma Cells Is Dependent on the Proapoptotic Activity of the Inhibitor of Apoptosis Protein Livin [J].
Lazar, Itay ;
Yaacov, Barak ;
Shiloach, Tamar ;
Eliahoo, Elad ;
Kadouri, Luna ;
Lotem, Michal ;
Perlman, Riki ;
Zakay-Rones, Zichria ;
Panet, Amos ;
Ben-Yehuda, Dina .
JOURNAL OF VIROLOGY, 2010, 84 (01) :639-646
[20]   The virus battles:: IFN induction of the antiviral state and mechanisms of viral evasion [J].
Levy, DE ;
García-Sastre, A .
CYTOKINE & GROWTH FACTOR REVIEWS, 2001, 12 (2-3) :143-156